(Q38098973)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Filippo Montemurro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Massimo Aglietta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Giorgio Valabrega

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

A Milani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

12 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1740-1748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23585514%20AND%20SRC:MED&resulttype=core&format=json

Anti-HER2 vaccines: new prospects for breast cancer therapy

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

The E75 HER2/neu peptide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

DNA vaccination against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Breast cancer vaccines: a clinical reality or fairy tale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT133